长春高新：子公司替勃龙片在境内获批上市

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of its drug, Teibolong Tablets, in China [1] Group 1: Company Information - Changchun Jinsai Pharmaceutical has developed Teibolong Tablets, which are classified as a selective estrogen receptor modulator [1] - The drug is categorized as a Class 4 oral chemical medication [1] - Teibolong Tablets are intended for the treatment of low estrogen symptoms caused by natural or surgical menopause in women [1]